BiotechTube

GB-0895 (SC) + GB-0895 (SC) + Placebo (SC) + Placebo (SC)

Phase 1Active
2 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma, COPD (Chronic Obstructive Pulmonary Disease)

Trial Timeline

Dec 12, 2023 → May 1, 2027

NCT ID
NCT07116889

About GB-0895 (SC) + GB-0895 (SC) + Placebo (SC) + Placebo (SC)

GB-0895 (SC) + GB-0895 (SC) + Placebo (SC) + Placebo (SC) is a phase 1 stage product being developed by Generate Biomedicines for Asthma. The current trial status is active. This product is registered under clinical trial identifier NCT07116889. Target conditions include Asthma, COPD (Chronic Obstructive Pulmonary Disease).

What happened to similar drugs?

20 of 20 similar drugs in Asthma were approved

Approved (20) Terminated (1) Active (0)
✅DuleraMerckApproved
✅Regadenoson + PlaceboAstellas PharmaApproved
✅levalbuterol HCl + albuterol SulfateSumitomo PharmaApproved
✅arformoterol (RR formoterol) + placebo + levalbuterolSumitomo PharmaApproved
✅Racemic albuterol (R+S albuterol) + Levalbuterol (R albuterol)Sumitomo PharmaApproved
✅BenralizumabAstraZenecaApproved
✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07116889Phase 1Active

Competing Products

20 competing products in Asthma

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
40
DuleraMerckApproved
43
BriquilimabJasper TherapeuticsPhase 1
11
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
35
RoflumilastAstraZenecaPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
OmalizumabDaiichi SankyoPhase 3
40
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
35
Regadenoson + PlaceboAstellas PharmaApproved
43
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
40
rabeprazoleEisaiPhase 3
40
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
35
Placebo + BrodalumabKyowa KirinPhase 2
27
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
35
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40